VOYA Investment Management’s Pacira BioSciences PCRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$644K Sell
28,506
-632
-2% -$14K ﹤0.01% 1626
2025
Q4
$754K Buy
29,138
+9,295
+47% +$221K ﹤0.01% 1583
2025
Q3
$511K Buy
19,843
+7,241
+57% +$178K ﹤0.01% 1754
2025
Q2
$301K Buy
12,602
+134
+1% +$3.38K ﹤0.01% 2145
2025
Q1
$310K Sell
12,468
-1,480
-11% -$35.4K ﹤0.01% 2104
2024
Q4
$263K Sell
13,948
-29,901
-68% -$525K ﹤0.01% 2265
2024
Q3
$660K Buy
43,849
+6,962
+19% +$119K ﹤0.01% 1849
2024
Q2
$1.06M Sell
36,887
-108
-0.3% -$3.07K ﹤0.01% 1600
2024
Q1
$1.08M Buy
36,995
+3,119
+9% +$95.8K ﹤0.01% 1598
2023
Q4
$1.14M Buy
33,876
+7,669
+29% +$224K ﹤0.01% 1617
2023
Q3
$804K Buy
26,207
+196
+0.8% +$7.07K ﹤0.01% 1761
2023
Q2
$1.04M Buy
26,011
+713
+3% +$29.5K ﹤0.01% 1643
2023
Q1
$1.03M Sell
25,298
-187,303
-88% -$7.45M ﹤0.01% 1634
2022
Q4
$8.21M Sell
212,601
-123,817
-37% -$6.02M 0.01% 790
2022
Q3
$17.9M Buy
336,418
+239,059
+246% +$13.3M 0.02% 532
2022
Q2
$5.68M Sell
97,359
-235,409
-71% -$15.4M 0.01% 694
2022
Q1
$25.4M Buy
332,768
+304,266
+1,068% +$20.3M 0.05% 288
2021
Q4
$1.72M Sell
28,502
-2,085
-7% -$115K ﹤0.01% 1236
2021
Q3
$1.71M Sell
30,587
-23
-0.1% -$1.33K ﹤0.01% 1254
2021
Q2
$1.86M Sell
30,610
-1,604
-5% -$102K ﹤0.01% 1246
2021
Q1
$2.26M Buy
32,214
+485
+2% +$34.6K ﹤0.01% 1130
2020
Q4
$1.9M Buy
31,729
+7,168
+29% +$420K ﹤0.01% 1173
2020
Q3
$1.48M Sell
24,561
-210
-0.8% -$12.2K ﹤0.01% 1133
2020
Q2
$1.3M Sell
24,771
-5,944
-19% -$248K ﹤0.01% 1170
2020
Q1
$1.03M Buy
30,715
+11,000
+56% +$457K ﹤0.01% 1214
2019
Q4
$893K Buy
19,715
+3,590
+22% +$152K ﹤0.01% 1517
2019
Q3
$614K Hold
16,125
﹤0.01% 1622
2019
Q2
$701K Sell
16,125
-218
-1% -$9.26K ﹤0.01% 1562
2019
Q1
$622K Sell
16,343
-367
-2% -$14.3K ﹤0.01% 1647
2018
Q4
$719K Buy
16,710
+520
+3% +$24.3K ﹤0.01% 1501
2018
Q3
$796K Sell
16,190
-175
-1% -$7.57K ﹤0.01% 1547
2018
Q2
$524K Sell
16,365
-1,190
-7% -$41.1K ﹤0.01% 1795
2018
Q1
$547K Sell
17,555
-570,892
-97% -$20.3M ﹤0.01% 1754
2017
Q4
$26.9M Sell
588,447
-2,548
-0.4% -$101K 0.06% 343
2017
Q3
$22.2M Buy
590,995
+125,156
+27% +$5.04M 0.05% 385
2017
Q2
$22.2M Buy
465,839
+21,231
+5% +$985K 0.05% 370
2017
Q1
$20.3M Sell
444,608
-95,033
-18% -$4.11M 0.05% 381
2016
Q4
$17.4M Buy
539,641
+187,663
+53% +$6.26M 0.04% 409
2016
Q3
$12K Sell
351,978
-13,750
-4% -$539K 0.02% 518
2016
Q2
$12.3M Buy
365,728
+93,563
+34% +$4.6M 0.03% 499
2016
Q1
$14.4M Sell
272,165
-50,350
-16% -$2.95M 0.04% 439
2015
Q4
$24.8M Sell
322,515
-44,450
-12% -$2.52M 0.06% 288
2015
Q3
$15.1M Buy
366,965
+77,725
+27% +$4.76M 0.04% 413
2015
Q2
$20.5M Buy
289,240
+94,745
+49% +$7.46M 0.05% 343
2015
Q1
$17.3M Sell
194,495
-94,009
-33% -$9.54M 0.04% 402
2014
Q4
$25.6M Buy
288,504
+141,704
+97% +$13.4M 0.06% 305
2014
Q3
$14.2M Buy
146,800
+32,170
+28% +$3.13M 0.03% 462
2014
Q2
$10.5M Buy
114,630
+98,661
+618% +$7.51M 0.02% 591
2014
Q1
$1.12M Hold
15,969
﹤0.01% 1409
2013
Q4
$918K Hold
15,969
﹤0.01% 1516
2013
Q3
$768K Hold
15,969
﹤0.01% 1592
2013
Q2
$463K Buy
+15,969
New +$462K ﹤0.01% 1898

Other funds holding PCRX

VOYA Investment Management's PCRX Position: Q1 2026 in Review

VOYA Investment Management reduced its Pacira BioSciences (PCRX) stake by 2.2% in Q1 2026, selling an estimated $14K and leaving 28,506 shares worth $644K. The position accounts for ﹤0.01% of the portfolio, ranked #1626.

VOYA Investment Management first reported a position in PCRX in Q2 2013 and has held it in 52 quarters since. The position peaked at $26.9M in Q4 2017. 241 funds tracked by Wall St. Rank hold PCRX as of Q1 2026.

  • VOYA Investment Management held 28,506 shares of Pacira BioSciences worth $644K as of Q1 2026.
  • VOYA Investment Management sold 632 Pacira BioSciences shares in Q1 2026, an estimated $14K.
  • Pacira BioSciences made up ﹤0.01% of VOYA Investment Management's portfolio in Q1 2026, its #1626 holding.
  • VOYA Investment Management first reported a position in Pacira BioSciences in Q2 2013 and has held it in 52 quarters since.
  • VOYA Investment Management's Pacira BioSciences position peaked at $26.9M in Q4 2017.
  • 241 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2026.

Based on VOYA Investment Management's 13F filing for Q1 2026, filed 12 May 2026.